TEVA insider filings
TEVA PHARMACEUTICAL INDUSTRIES LTD — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-17. Screen TEVA transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 15 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 17 legs across 10 filings by 8 insiders — 814,064 shares, $33,242,786 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 367,600 shares @ $39.06 ($14,356,802) by MIGNONE ROBERTO, filed 2026-09-22.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| MIGNONE ROBERTO — Director | 1 | — | 1 leg · 367,600 sh · $14,356,802 | — |
| Francis Richard D — President and CEO | 1 | — | 1 leg · 250,000 sh · $10,559,175 | — |
| Sabag Mark — See "Remarks" | 2 | — | 2 legs · 90,710 sh · $3,902,274 | 4 |
| Daniell Richard — EVP, Europe Commercial | 1 | — | 2 legs · 45,003 sh · $1,928,944 | 4 |
| Weiss Amir — Chief Accounting Officer | 2 | — | 5 legs · 26,734 sh · $1,099,350 | 4 |
| Bergwerk Dov — Interim Chief Legal Officer | 4 | — | 2 legs · 26,260 sh · $1,095,567 | 7 |
| Savage Brian — Interim Chief Legal Officer | 1 | — | 3 legs · 7,342 sh · $285,215 | 2 |
| Satchi-Fainaro Ronit — Director | 1 | — | 1 leg · 415 sh · $15,459 | — |
| BRAILER DAVID J — Director | 2 | — | — | 1 |
Recent insider filings — TEVA PHARMACEUTICAL INDUSTRIES LTD
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | Bergwerk Dov — Interim Chief Legal Officer | Option exercise (M): 8,370 · Option exercise (M): 8,370 (derivative) @ $0 | EDGAR |
| 2026-11-12 | 4 | Daniell Richard — EVP, Europe Commercial | Option exercise (M): 25,000 @ $34.70 · Sale (S): 25,000 @ $42.91 · Option exercise (M): 20,003 @ $34.70 · Sale (S): 20,003 @ $42.80 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 20,003 (derivative) @ $0 | EDGAR |
| 2026-11-12 | 4 | Sabag Mark — See "Remarks" | Option exercise (M): 44,710 @ $34.90 · Sale (S): 44,710 @ $44.14 · Option exercise (M): 44,710 (derivative) @ $0 | EDGAR |
| 2026-11-12 | 4 | Francis Richard D — President and CEO | Sale (S): 250,000 @ $42.24 | EDGAR |
| 2026-11-12 | 4 | Bergwerk Dov — Interim Chief Legal Officer | Grant/award (A): 9,433 (derivative) @ $0 | EDGAR |
| 2026-11-12 | 4 | Weiss Amir — Chief Accounting Officer | Option exercise (M): 7,755 @ $34.70 · Sale (S): 662 @ $43.15 · Sale (S): 7,093 @ $43.03 · Sale (S): 9,534 @ $43.03 · Option exercise (M): 7,755 (derivative) @ $0 | EDGAR |
| 2026-11-12 | 4 | BRAILER DAVID J — Director | Grant/award (A): 3,326 (derivative) @ $0 | EDGAR |
| 2026-11-12 | 3 | BRAILER DAVID J — Director | Holdings only — no transactions reported | EDGAR |
| 2026-11-06 | 4 | Sabag Mark — See "Remarks" | Option exercise (M): 46,000 @ $34.90 · Sale (S): 46,000 @ $41.93 · Option exercise (M): 46,000 (derivative) @ $0 | EDGAR |
| 2026-11-06 | 4 | Bergwerk Dov — Interim Cheif Legal Officer | Option exercise (M): 17,505 @ $34.70 · Sale (S): 17,505 @ $41.72 · Option exercise (M): 8,755 @ $28.98 · Sale (S): 8,755 @ $41.72 · Option exercise (M): 17,505 (derivative) @ $0 · Option exercise (M): 8,755 (derivative) @ $0 | EDGAR |
| 2026-10-08 | 3 | Bergwerk Dov — Interim Cheif Legal Officer | Holdings only — no transactions reported | EDGAR |
| 2026-09-22 | 4 | Savage Brian — Interim Chief Legal Officer | Option exercise (M): 4,503 @ $34.70 · Sale (S): 4,503 @ $38.69 · Sale (S): 2,525 @ $39.15 · Sale (S): 314 @ $38.70 · Option exercise (M): 4,503 (derivative) @ $34.70 | EDGAR |
| 2026-09-22 | 4 | MIGNONE ROBERTO — Director | Sale (S): 367,600 @ $39.06 | EDGAR |
| 2026-08-25 | 4 | Satchi-Fainaro Ronit — Director | Sale (S): 415 @ $37.25 | EDGAR |
| 2026-08-25 | 4 | Weiss Amir — Chief Accounting Officer | Sale (S): 6,945 @ $37.61 · Option exercise (M): 2,500 @ $19.61 · Sale (S): 2,500 @ $37.63 · Option exercise (M): 2,500 (derivative) @ $19.16 | EDGAR |
| 2026-08-19 | 4 | Lippman Evan — EVP, Business Development | Sale (S): 18,600 @ $36.57 | EDGAR |
| 2026-08-10 | 4 | Zaks Tal Zvi — Director | Sale (S): 17 @ $34.87 | EDGAR |
| 2026-08-05 | 4 | Jover Placid — See "Remarks" | Option exercise (M): 12,827 · Sale (S): 12,827 @ $34.88 · Option exercise (M): 12,827 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Hughes Eric A — See "Remarks" | Option exercise (M): 52,744 · Sale (S): 25,578 @ $34.88 · Option exercise (M): 52,744 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Shields Matthew — EVP, Global Operations | Sale (S): 9,989 @ $32.19 | EDGAR |
| 2026-06-16 | 4 | Kalif Eliyahu Sharon — EVP, Chief Financial Officer | Sale (S): 106,563 @ $34.10 | EDGAR |
| 2026-06-08 | 4 | Lichtenstein Chen — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Satchi-Fainaro Ronit — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Elstein Amir — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Zaks Tal Zvi — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Nisen Perry — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Francis Richard D — President and CEO | Option exercise (M): 13,043 · Sale (S): 6,153 @ $34.35 · Option exercise (M): 13,043 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Crane Rosemary A — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | MIGNONE ROBERTO — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | BARER SOL J — Director | Option exercise (M): 21,739 · Option exercise (M): 21,739 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | LIEBERMAN GERALD M — Director | Option exercise (M): 14,492 · Option exercise (M): 14,492 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Shields Matthew — EVP, Global Operations | Option exercise (M): 16,195 · Sale (S): 16,195 @ $32.87 · Option exercise (M): 16,195 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Lichtenstein Chen — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Satchi-Fainaro Ronit — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Elstein Amir — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Zaks Tal Zvi — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Nisen Perry — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Crane Rosemary A — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | MIGNONE ROBERTO — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | BARER SOL J — Director | Grant/award (A): 10,863 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | LIEBERMAN GERALD M — Director | Grant/award (A): 7,242 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Lippman Evan — EVP, Business Development | Option exercise (M): 11,841 · Sale (S): 5,746 @ $35.58 · Option exercise (M): 74,008 · Sale (S): 35,912 @ $35.58 · Option exercise (M): 11,841 (derivative) @ $0 · Option exercise (M): 74,008 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Kalif Eliyahu Sharon — EVP, Chief Financial Officer | Sale (S): 153,251 @ $35.61 | EDGAR |
| 2026-05-07 | 4 | Weiss Amir — Chief Accounting Officer | Sale (S): 10,679 @ $36 | EDGAR |
| 2026-05-07 | 4 | Daniell Richard — EVP, Europe Commercial | Sale (S): 30,000 @ $35.40 | EDGAR |
| 2026-05-04 | 4 | Fox Christine — EVP, U.S. Commercial | Sale (S): 21,258 @ $35.31 | EDGAR |
| 2026-05-04 | 4 | Sabag Mark — See "Remarks" | Sale (S): 144,180 @ $34.99 | EDGAR |
| 2026-03-19 | 4 | Sabag Mark — See "Remarks" | Sale (S): 62,102 @ $30.14 | EDGAR |
| 2026-03-09 | 4 | Sabag Mark — See "Remarks" | Option exercise (M): 15,723 · Option exercise (M): 15,723 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Francis Richard D — President and CEO | Option exercise (M): 42,452 · Sale (S): 20,025 @ $31.67 · Option exercise (M): 42,452 (derivative) @ $0 | EDGAR |
Recent 8-K events — TEVA PHARMACEUTICAL INDUSTRIES LTD
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-09-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TEVA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs